MX336903B - Agentes terapeuticos para el tratamiento de enfermedades asociadas con una proliferacion celular indeseada. - Google Patents
Agentes terapeuticos para el tratamiento de enfermedades asociadas con una proliferacion celular indeseada.Info
- Publication number
- MX336903B MX336903B MX2011010425A MX2011010425A MX336903B MX 336903 B MX336903 B MX 336903B MX 2011010425 A MX2011010425 A MX 2011010425A MX 2011010425 A MX2011010425 A MX 2011010425A MX 336903 B MX336903 B MX 336903B
- Authority
- MX
- Mexico
- Prior art keywords
- cell proliferation
- diseases associated
- treatment
- proliferation
- therapeutic agents
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 230000004663 cell proliferation Effects 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 230000035755 proliferation Effects 0.000 abstract 2
- 210000000130 stem cell Anatomy 0.000 abstract 2
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 206010018338 Glioma Diseases 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000004393 prognosis Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2093—Leukaemia inhibitory factor [LIF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Toxicology (AREA)
Abstract
La presente invención se refiere a la observación de que LIF es capaz de activar la autorrenovación de células madre tumorales en cánceres, en particular en gliomas, lo que indica que la inhibición de LIF, y en general de citocinas de tipo IL-6, puede usarse en composiciones terapéuticas para el tratamiento de enfermedades asociadas con una proliferación indeseada. La invención también se refiere a un procedimiento para la identificación de compuestos capaces de bloquear/inhibir la proliferación de células madre, y a un procedimiento in vitro para el diagnóstico de enfermedades asociadas con una proliferación celular indeseada en un sujeto o para determinar la predisposición de un sujeto a padecer dicha enfermedad asociada con una proliferación celular indeseada, o para el pronóstico de la esperanza de vida media de sujetos que padecen dichos tumores.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200900928A ES2363358B1 (es) | 2009-04-03 | 2009-04-03 | Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable. |
| PCT/EP2010/054499 WO2010115868A2 (en) | 2009-04-03 | 2010-04-06 | Therapeutic agents for the treatment of diseases associated with undesired cell proliferation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2011010425A MX2011010425A (es) | 2012-03-06 |
| MX336903B true MX336903B (es) | 2016-02-04 |
Family
ID=42342718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011010425A MX336903B (es) | 2009-04-03 | 2010-04-06 | Agentes terapeuticos para el tratamiento de enfermedades asociadas con una proliferacion celular indeseada. |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US10100112B2 (es) |
| EP (2) | EP2414394A2 (es) |
| JP (5) | JP6207836B2 (es) |
| KR (6) | KR102373754B1 (es) |
| CN (2) | CN102574918A (es) |
| AU (1) | AU2010233791B2 (es) |
| BR (1) | BRPI1015369A2 (es) |
| CA (1) | CA2757680C (es) |
| CY (1) | CY1124148T1 (es) |
| DK (1) | DK3045474T3 (es) |
| EA (1) | EA201101450A1 (es) |
| ES (2) | ES2363358B1 (es) |
| HR (1) | HRP20210352T1 (es) |
| HU (1) | HUE054196T2 (es) |
| IL (1) | IL215467A (es) |
| LT (1) | LT3045474T (es) |
| MX (1) | MX336903B (es) |
| PL (1) | PL3045474T3 (es) |
| PT (1) | PT3045474T (es) |
| SG (2) | SG175032A1 (es) |
| SI (1) | SI3045474T1 (es) |
| SM (1) | SMT202100153T1 (es) |
| WO (1) | WO2010115868A2 (es) |
| ZA (1) | ZA201107215B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2686093T3 (es) * | 2005-07-19 | 2018-10-16 | Stemgen S.P.A. | Inhibición del potencial tumorigénico de células madre tumorales por BMP-4 |
| EP2371860A1 (en) | 2010-04-05 | 2011-10-05 | Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron | Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation |
| JP2015071566A (ja) * | 2013-10-03 | 2015-04-16 | 住友ベークライト株式会社 | Ｆｇｆ４遺伝子増幅腫瘍の医薬組成物 |
| WO2015136557A2 (en) * | 2014-03-11 | 2015-09-17 | Godavari Biorefineries Limited | Cancer stem cell targeting compounds |
| KR102503476B1 (ko) * | 2014-06-30 | 2023-02-24 | 알토 바이오사이언스 코포레이션 | Il-15-베이즈드 분자 및 이의 사용 방법 |
| EP3191129A4 (en) * | 2014-09-10 | 2018-03-14 | The Regents of The University of California | TARGETING K-RAS-MEDIATED SIGNALING PATHWAYS AND MALIGNANCY BY ANTI-hLIF ANTIBODIES |
| EP3067422B1 (en) * | 2015-03-13 | 2024-07-31 | Sabanci Üniversitesi | Ct-1 inhibitors |
| EP3273983B1 (en) | 2015-03-23 | 2021-05-05 | Evestra, Inc. | Novel cytotoxic agents that preferentially target leukemia inhibitory factor (lif) for the treatment of malignancies and as new contraceptive agents |
| EP3173483A1 (en) | 2015-11-27 | 2017-05-31 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Agents for the treatment of diseases associated with undesired cell proliferation |
| AU2017381585B2 (en) | 2016-12-19 | 2025-02-13 | Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats | Antibodies against LIF and uses thereof |
| WO2018115960A1 (en) | 2016-12-19 | 2018-06-28 | Mosaic Biomedicals, S.L. | Antibodies against lif and uses thereof |
| EP3794031A2 (en) * | 2018-05-14 | 2021-03-24 | MedImmune Limited | Antibodies against lif and dosage forms thereof |
| US20210253691A1 (en) * | 2018-06-18 | 2021-08-19 | Medimmune Limited | Methods for improving response to anti-lif antibody treatment in individuals with cancer |
| US20210187106A1 (en) * | 2018-06-18 | 2021-06-24 | Medimmune Limited | Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer |
| WO2020056349A2 (en) * | 2018-09-13 | 2020-03-19 | Evestra, Inc. | Lif/lifr antagonist oncology and nonmalignant diseases |
| MX2021012163A (es) * | 2019-04-17 | 2022-01-31 | Univ Hiroshima | Agente terapeutico para cancer urologico que se caracteriza por ser administrado con un inhibidor de il-6 y un inhibidor de ccr2 en combinacion. |
| CN111020030A (zh) * | 2019-12-03 | 2020-04-17 | 中山大学 | 一种骨肉瘤干细胞标志物及其应用、试剂盒 |
| EP3988116A1 (en) * | 2020-10-23 | 2022-04-27 | Consejo Superior De Investigaciones Científicas (CSIC) | Methods and compositions for the treatment of hematologic malignancies |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
| NZ227332A (en) | 1987-12-15 | 1991-08-27 | Gene Shears Pty Ltd | Ribozymes, production and use |
| US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
| US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
| US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
| GB9004890D0 (en) * | 1990-03-05 | 1990-05-02 | Heath John K | Leukaemia inhibitory factor |
| DE69233254T2 (de) | 1991-06-14 | 2004-09-16 | Genentech, Inc., South San Francisco | Humanisierter Heregulin Antikörper |
| JPH05304986A (ja) * | 1992-04-28 | 1993-11-19 | Tosoh Corp | ｇｐ１３０蛋白質に対するモノクロ−ナル抗体 |
| WO1993023556A1 (en) | 1992-05-08 | 1993-11-25 | Genentech, Inc. | Antibodies to leukemia inhibitory factor |
| GB9413316D0 (en) | 1994-07-01 | 1994-08-24 | Cancer Res Campaign Tech | Novel proteins |
| US6251588B1 (en) | 1998-02-10 | 2001-06-26 | Agilent Technologies, Inc. | Method for evaluating oligonucleotide probe sequences |
| US20050147609A1 (en) | 1998-05-15 | 2005-07-07 | Genentech, Inc. | Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis |
| KR100940380B1 (ko) | 1999-01-15 | 2010-02-02 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| DE60040651D1 (de) * | 1999-02-12 | 2008-12-11 | Emd Serono Res Ct Inc | Methoden zur behandlung von tumoren und metastasen unter verwendung einer anti-angiogenen und immun-therapien |
| US6110462A (en) | 1999-03-03 | 2000-08-29 | The Scripps Research Institute | Enzymatic DNA molecules that contain modified nucleotides |
| US7084257B2 (en) | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
| EP1497445A2 (en) | 2002-04-01 | 2005-01-19 | Human Genome Sciences, Inc. | Antibodies that specifically bind to gmad |
| JP2006512924A (ja) * | 2002-08-15 | 2006-04-20 | ジェンザイム・コーポレーション | 脳内皮細胞発現パターン |
| US20060078533A1 (en) * | 2004-10-12 | 2006-04-13 | Omoigui Osemwota S | Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| WO2004067778A2 (en) * | 2003-01-28 | 2004-08-12 | University Of South Florida | Differentially expressed genes in large granular lymphocyte leukemia |
| WO2005030803A1 (en) * | 2003-09-29 | 2005-04-07 | The Walter And Eliza Hall Institute Of Medical Research | Therapeutic molecules |
| JPWO2005116204A1 (ja) * | 2004-05-11 | 2008-06-19 | 株式会社アルファジェン | Ｒｎａ干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法 |
| MX2011002082A (es) * | 2008-08-29 | 2011-06-20 | Genentech Inc | Diagnostico y tratamientos para los tumores independientes del vegf. |
| EP2371860A1 (en) * | 2010-04-05 | 2011-10-05 | Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron | Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation |
| WO2018115960A1 (en) * | 2016-12-19 | 2018-06-28 | Mosaic Biomedicals, S.L. | Antibodies against lif and uses thereof |
-
2009
- 2009-04-03 ES ES200900928A patent/ES2363358B1/es not_active Withdrawn - After Issue
-
2010
- 2010-04-06 EA EA201101450A patent/EA201101450A1/ru unknown
- 2010-04-06 KR KR1020207017470A patent/KR102373754B1/ko active IP Right Grant
- 2010-04-06 SG SG2011071834A patent/SG175032A1/en unknown
- 2010-04-06 EP EP10713619A patent/EP2414394A2/en not_active Ceased
- 2010-04-06 SM SM20210153T patent/SMT202100153T1/it unknown
- 2010-04-06 EP EP16155009.0A patent/EP3045474B1/en active Active
- 2010-04-06 AU AU2010233791A patent/AU2010233791B2/en active Active
- 2010-04-06 DK DK16155009.0T patent/DK3045474T3/da active
- 2010-04-06 CN CN2010800246730A patent/CN102574918A/zh active Pending
- 2010-04-06 LT LTEP16155009.0T patent/LT3045474T/lt unknown
- 2010-04-06 KR KR1020227007752A patent/KR20220035978A/ko not_active IP Right Cessation
- 2010-04-06 PL PL16155009T patent/PL3045474T3/pl unknown
- 2010-04-06 KR KR1020187018827A patent/KR20180079470A/ko not_active Application Discontinuation
- 2010-04-06 CA CA2757680A patent/CA2757680C/en active Active
- 2010-04-06 JP JP2012502710A patent/JP6207836B2/ja active Active
- 2010-04-06 US US13/138,804 patent/US10100112B2/en active Active
- 2010-04-06 CN CN201711070081.2A patent/CN107964043A/zh active Pending
- 2010-04-06 MX MX2011010425A patent/MX336903B/es active IP Right Grant
- 2010-04-06 ES ES16155009T patent/ES2864639T3/es active Active
- 2010-04-06 KR KR1020197022597A patent/KR20190093691A/ko not_active Application Discontinuation
- 2010-04-06 SI SI201032059T patent/SI3045474T1/sl unknown
- 2010-04-06 KR KR1020117026088A patent/KR20120100703A/ko active Application Filing
- 2010-04-06 KR KR1020177030504A patent/KR20170121319A/ko not_active Application Discontinuation
- 2010-04-06 BR BRPI1015369-1A patent/BRPI1015369A2/pt not_active Application Discontinuation
- 2010-04-06 SG SG10202010568RA patent/SG10202010568RA/en unknown
- 2010-04-06 HU HUE16155009A patent/HUE054196T2/hu unknown
- 2010-04-06 PT PT161550090T patent/PT3045474T/pt unknown
- 2010-04-06 WO PCT/EP2010/054499 patent/WO2010115868A2/en active Application Filing
-
2011
- 2011-10-02 IL IL215467A patent/IL215467A/en active IP Right Grant
- 2011-10-03 ZA ZA2011/07215A patent/ZA201107215B/en unknown
-
2015
- 2015-09-11 JP JP2015178986A patent/JP2016040255A/ja active Pending
-
2018
- 2018-08-14 JP JP2018152551A patent/JP2019006784A/ja active Pending
- 2018-08-28 US US16/115,191 patent/US20190211095A1/en not_active Abandoned
-
2020
- 2020-02-04 JP JP2020016672A patent/JP2020090522A/ja active Pending
- 2020-08-24 US US17/001,530 patent/US11999782B2/en active Active
-
2021
- 2021-03-02 HR HRP20210352TT patent/HRP20210352T1/hr unknown
- 2021-03-18 CY CY20211100232T patent/CY1124148T1/el unknown
- 2021-11-17 JP JP2021186785A patent/JP7197665B2/ja active Active
-
2024
- 2024-05-01 US US18/652,603 patent/US20240400667A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011010425A (es) | Agentes terapeuticos para el tratamiento de enfermedades asociadas con una proliferacion celular indeseada. | |
| MX365054B (es) | Anticuerpo que reconoce el factor inhibidor de la leucemia humana (lif) y uso de anticuerpos anti-lif en el tratamiento de enfermedades asociadas a una proliferacion celular no deseada. | |
| MX2009012722A (es) | Variantes geneticas sobre chr 5p12 y 10q26 como marcadores para el uso en la evaluacion del riesgo, diagnostico, pronostico y tratamiento del cancer de mama. | |
| WO2012006589A3 (en) | Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling | |
| MX2012009030A (es) | Identificacion de mutacion lkb1 como biomarcador predictivo para sensibilidad a inhibidores de tor cinasa. | |
| MX2009002936A (es) | Biomarcadores de la modulacion de objetivo, eficacia, diagnostico, y/o pronostico para los inhibidores de raf. | |
| WO2007081680A3 (en) | Microrna expression abnormalities in pancreatic endocrine and acinar tumors | |
| MX2009010439A (es) | Variantes geneticas de chr2 y chr16 como marcadores para el uso en valoracion, diagnosis, prognosis y tratamiento de riesgo de cancer de mama. | |
| WO2012081898A3 (ko) | 위암의 예후 예측용 마커 및 이를 이용하는 위암의 예후 예측 방법 | |
| MX2011009167A (es) | Combinaciones de compuestos inhibidores de fosfoinositida 3-cinasa y agentes quimioterapeuticos para el tratamiento contra neoplasia hemotopoyeticas malignas. | |
| WO2011035143A3 (en) | Methods and compositions for inhibiting rho-mediated diseases and conditions | |
| WO2010017515A3 (en) | Breast cancer specific markers and methods of use | |
| MY158829A (en) | 5-anilinoimidazopyridines and methods of use | |
| EA201000016A1 (ru) | Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями | |
| MX2011007397A (es) | Inhibidores de dpp-iv para el tratamiento de la diabetes en pacientes pediatricos. | |
| WO2006133361A3 (en) | Use of gene expression profiling to predict survival in cancer patient | |
| SG178899A1 (en) | Raf inhibitor compounds and methods of use thereof | |
| MX2012006822A (es) | 1,7-diazacarbazoles y metodos de uso. | |
| SG178900A1 (en) | Raf inhibitor compounds and methods of use thereof | |
| EA201071422A1 (ru) | Способы лечения заболеваний, связанных с мейотическим кинезином | |
| WO2008092002A3 (en) | Compositions and methods for treating and diagnosing pancreatic cancer | |
| WO2006039582A3 (en) | Compositions and methods for diagnosing and treating brain cancer and identifying neural stem cells | |
| Zhang et al. | Correlation of KLF4 and SPARC expression with the clinical characteristics of non-small cell lung cancer | |
| TW200951438A (en) | Methods for identifying nuclear receptor/ligand combinations for targeting brain tumor stem cells and for their use | |
| EA200802356A1 (ru) | Способ выявления и диагностики злокачественного новообразования, включающий праймеры и зонды для специфичного выявления маркера mage-a3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |